Unrated Drug recall · FDA · Published March 6, 2026

Payless Compounds Semaglutide Injectable Recall: Lack of Sterility Assurance

Payless Compounds recalls Semaglutide-Glycine-Cyanocobalamin injectables due to lack of sterility assurance. Affected vials from specific lot numbers may pose infection risks.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0471-2026Drug Payless Compounds ›

Recall notice

Lack of Assurance of Sterility

Take action

Contact the company & request your remedy

Email01-27-2026@14s.5

Recalling firmPAYLESS COMPOUNDERS, LLC8505 Sw Creekside Pl Ste 110 · Beaverton, OR 97008-7128

Opens pre-filled in Gmail, Outlook, Yahoo, or your mail app.

✎ GovInfoNow plain-language explainer

Payless Compounds is recalling certain semaglutide injectable vials because they may not be sterile, which could lead to infections if used. This recall affects patients prescribed these medications through a specific pharmacy. Read more at govinfonow.com/recall/31451-payless-compounds-semaglutide-injectable-recall-lack-of-sterility-assurance.

Source Summary by GovInfoNow · govinfonow.com/recall/31451-payless-compounds-semaglutide-injectable-recall-lack-of-sterility-assurance · Updated August 18, 2026 · FDA enforcement record: FDA #D-0471-2026

Cite this page

“Payless Compounds Semaglutide Injectable Recall: Lack of Sterility Assurance.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/31451-payless-compounds-semaglutide-injectable-recall-lack-of-sterility-assurance. Based on FDA recall #D-0471-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0471-2026%22&limit=1).

The FDA announced on March 6, 2026, that Payless Compounds is recalling Semaglutide-Glycine-Cyanocobalamin Injectable vials due to a lack of assurance of sterility. The recall involves 91 vials distributed in Oregon.

How to tell if you have it

Brand: Payless Compounds
Product: Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials
Lot Number: 01-27-2026@14S.5

The hazard

The product poses a risk due to a lack of assurance of sterility. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show other recent recalls of similar products include New Life Pharma Semaglutide Injections Recall (2026-02-26) and New Life Pharma Semaglutide Inj 2mg Vial Recall (2026-02-26). A ProRx Semaglutide Injection Recall for lack of sterility assurance risk occurred on 2025-10-15.

How to tell if you have this one

Check for vials labeled 'Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL' with lot number 01-27-2026@14S.5 from Northwest Compounders in Beaverton, Oregon.

Brand
Payless Compounds
Category
Drug

Based on the official FDA remedy

What to do — step by step

Check Vial Lot Number
Look for the lot number 01-27-2026@14S.5 on the vial label to confirm if it's affected.

Where it went and when

Where it was distributed

Distributed in Oregon.

FDA distribution: “OR” States read from FDA’s own wording; “not listed” means the notice does not name it.

States: Oregon.

Recall timeline

FDA published this recall 47 days after the firm started it.

Mar 6, 2026Firm started the recall
Apr 13, 2026FDA classified it Class II
Apr 22, 2026Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Take action

Contact Payless Compounds

We’ve drafted a message you can send Payless Compounds to request your refund or repair — edit it as you like.

✉️ Open in email

Subject: Recall D-0471-2026 — Payless Compounds Semaglutide Injectable Recall: Lack of Sterility Assurance

Hello,

I own a Payless Compounds Semaglutide Injectable Recall: Lack of Sterility Assurance that is covered by recall D-0471-2026 from Payless Compounds.

I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this?

Thank you.

Similar recalls

Latest drug recalls

Keep exploring

Link to this recall

<a href="https://govinfonow.com/recall/31451-payless-compounds-semaglutide-injectable-recall-lack-of-sterility-assurance">Payless Compounds Semaglutide Injectable Recall: Lack of Sterility Assurance (GovInfoNow)</a>

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

Official source: FDA Recall #D-0471-2026 (March 6, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0471-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.